| William Scott Riley, RPH | |
|
849 S Three Notch St, Andalusia, AL 36420-5325 | |
| (334) 504-5462 | |
| (334) 222-6988 |
| Full Name | William Scott Riley |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 849 S Three Notch St, Andalusia, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245848845 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 11668 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| William Scott Riley, RPH 849 S Three Notch St, Andalusia, AL 36420-5325 Ph: (334) 504-5462 | William Scott Riley, RPH 849 S Three Notch St, Andalusia, AL 36420-5325 Ph: (334) 504-5462 |
News Archive
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Starting medication for multiple sclerosis (MS) in people who show the beginning signs of the disease is associated with prolonging the time before the disease is definitively diagnosed, according to a long-term study published in the August 10, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.
A new drug launched today could help in the fight against what experts and campaigners are calling a 'major patient safety issue' - the prevention of hospital-acquired DVT (deep vein thrombosis).
Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala. At the same time, the company secures substantial financing to complete the clinical trial.
Hana Biosciences Inc.,, today announced complete data from its pivotal, Phase 2 RALLY clinical trial for Marqibo® (vincristine sulfate liposome injection) for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Results from the RALLY trial demonstrated compelling evidence of single-agent, anti-leukemic activity in an advanced, heavily pre-treated, adult ALL population.
› Verified 8 days ago
Ashley Brooke Maloy Chapman, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 822 S Three Notch St, Andalusia, AL 36420 Phone: 334-582-3784 Fax: 334-582-3785 | |
William Ray, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1017 River Falls St, Andalusia, AL 36420 Phone: 334-222-9414 | |
Sandra Lasiter, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1017 River Falls St, Andalusia, AL 36420 Phone: 334-222-9414 Fax: 334-222-0797 | |
Horace J Bailey, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 224 S Three Notch St, Andalusia, AL 36420 Phone: 334-222-1131 Fax: 334-222-6212 | |
Judy Rowe St John, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 837 S Three Notch St, Andalusia, AL 36420 Phone: 334-222-1141 Fax: 334-222-8361 | |
Mr. Austin Jeffery Bailey, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 324 W Bypass, Andalusia, AL 36420 Phone: 334-427-1111 Fax: 334-427-1116 |